

CytoDyn Inc.
Form 8-K
June 07, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 7, 2018

CytoDyn Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

1111 Main Street, Suite 660

000-49908
(SEC

File Number)

75-3056237
(I.R.S. Employer

Identification No.)

98660

Vancouver, Washington
(Address of principal executive offices) **(Zip Code)**
Registrant's telephone number, including area code: (360) 980-8524

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.03 Amendments to the Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 7, 2018, CytoDyn Inc., a Delaware corporation (the Company), filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the **Certificate of Amendment**) to its Certificate of Incorporation, increasing the total number of authorized shares of Common Stock to 450,000,000. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated by reference herein. The Company's stockholders approved the Certificate of Amendment at a special meeting of stockholders on June 7, 2018.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 7, 2018, the Company held a special meeting of stockholders at which the stockholders approved the Certificate of Amendment to increase the number of authorized shares of common stock to 450,000,000 from 375,000,000.

The stockholders also approved an adjournment of the special meeting, if it had been necessary to solicit additional proxies, had there been insufficient votes to approve the Certificate of Amendment.

The final results for each proposal are set forth below. A more detailed description of each proposal is set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on May 8, 2018.

Proposal No. 1 Certificate of Amendment to Increase the Number of Authorized Shares of Common Stock.

For	Against	Abstained
128,956,045	13,004,185	404,497

Proposal No. 2 Adjournment of the Special Meeting.

For	Against	Abstained
134,107,725	7,439,569	817,433

Item 9.01. Financial Statements and Exhibits.**Exhibit**

(d)	No.	Description.
	3.1	<u>Certificate of Amendment to the Certificate of Incorporation of CytoDyn Inc.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn Inc.

June 7, 2018

By: */s/ Michael D. Mulholland*
Name: Michael D. Mulholland
Title: Chief Financial Officer